Altered expression of hepatic carcinogen metabolizing enzymes with liver injury in HBV transgenic mouse lineages expressing various amounts of hepatitis B surface antigen

Liver

Volumn 19, Issue 2, 1999, Pages 81-87

  Chemin, I ^a,c   Ohgaki, H ^d   Chisari, F V ^b   Wild, C P ^d  

^a INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

^b SCRIPPS RESEARCH INSTITUTE   (United States)

^c INSERM   (France)

^d NONE

Author keywords

Cytochrome P450s; Glutathione S transferases; Hepatitis B virus; Hepatocellular carcinoma

Indexed keywords

CARCINOGEN; CYTOCHROME P450; ENVELOPE PROTEIN; ENZYME; GLUTATHIONE TRANSFERASE; HEPATITIS B SURFACE ANTIGEN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; ENZYME BLOOD LEVEL; ENZYME SYNTHESIS; GENE EXPRESSION; HEPATITIS B; IMMUNOHISTOCHEMISTRY; INFECTION; LIVER CANCER; LIVER CARCINOGENESIS; LIVER CELL; LIVER CELL DAMAGE; LIVER INJURY; MALE; METABOLISM; MOUSE; NONHUMAN; STAINING; TRANSGENE; TRANSGENIC MOUSE;

EID: 0033041076     PISSN: 01069543     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1478-3231.1999.tb00015.x     Document Type: Article

References (35)

1. IARC Monograph on the Evaluation of Carcinogenic Risks to Humans, Vol 59, Hepatitis Viruses: IARC Lyon, 1994.
2. CHISARI F V. Hepatitis B virus transgenic mice: insights into the virus and the disease. Hepatology 1995; 22: 1316-25.
3. IARC Monograph on the Evaluation of Carcinogenic Risks to Humans, Vol 56, Some Naturally occurring substances: Some food items and constitutents, heterocyclic amines and mycotoxins, IARC Lyon, 1993.
4. QIAN G S, ROSS R K, YU M C, et al. A follow-up study of urinary markers of aflatoxin exposure and liver cancer risk in Shanghai, People's Republic of China. Cancer Epidemiol Biomarkers Prev. 1994: 3: 3-10.
5. ROSS R K, YUAN J M, YU M C. Urinary aflatoxin biomarkers and risk of hepatocellular carcinoma. Lancet 1992; 339: 943-6.
6. HARRIS C C. Solving the viral-chemical puzzle of human liver carcinogenesis. Cancer Epidemiol Biomarkers Prev. 1994; 3: 1-2.
7. WILD C P, JANSEN L A M, COVA L, MONTESANO R. Molecular dosimetry of aflatoxin exposure:contribution to understanding the multifactorial etiopathogenesis of primary hepatocellular carcinoma with particular reference to hepatitis B virus. Environ Health Perspect 1993; 99: 115-22.
8. DE FLORA S, HIETANEN E, BARTSCH H, et al. Enhanced metabolic activation of chemical hepatocarcinogens in woodchucks infected with hepatitis B virus. Carcinogenesis 1989; 10: 1099-1106.
9. SELL S, HUNT J M, DUNSFORD H A, CHISARI F V. Synergy between hepatitis B virus expression and chemical hepatocarcinogenesis in transgenic mice. Cancer Res 1991; 51: 1278-85.
10. KIRBY G, CHEMIN I, MONTSANO R, CHISARI F V, LANG M A, WILD C P. Induction of specific cytochrome P450s involved in aflatoxin B1 metabolism in hepatitis B virus transgenic mice. Mol Carcinog 1994; 11: 74-80.
11. ANDO K, MORIYAMA T, GUIDOTTI L G, et al. Mechanisms of class I restricted immunopathology A transgenic mouse model of fulminant hepatitis. J Exp Med 1993; 178: 1541-54.
12. CHEMIN I, TAKAHASHI S, BELLOC C, et al. Differential induction of carcinogen metabolizing enzymes in a transgenic mouse model of fulminant hepatitis. Hepatology 1996; 24: 649-56.
13. FILIPPI P, BURAS J, McLACHLAN A, et al. Overproduction of the hepatitis B virus large envelope polypeptide causes filament storage, ground glass-cell formation, hepatocellular injury and nodular hyperplasia in transgenic mice. In: Viral hepatitis and Liver Disease, Zuckerman A J (ed) Alan R Liss Inc, 1988; pp 632-40.
14. CHISARI F V, PINKERT C A, MILICH D R, et al. A transgenic mice model of the chronic hepatitis B surface antigen carrier state. Science 1985; 230: 1157.
15. CHISARI F V, FILLIPI P, McLAHAN A, et al. Expression of hepatitis B large envelope polypeptide inhibits hepatitis B surface antigen secretion in transgenic mice. J Virol 1986; 60: 880-97.
16. CHISARI F V, FILLIPI P, BURAS, et al. Structural and pathological effects of hepatitis B virus large envelope polypeptide synthesis in transgenic mice. Proc Natl Acad Sci USA 1987; 84: 6909-13.
17. HONKAKOSKI P, LANG M. Mouse liver phenobarbital-inducible P450 system : purification, characterization and differential inducibility of four cytochrome P450 isozymes from the D2 mouse. Arch Biochem Biophys 1989; 273: 42-57.
18. QUINN B A, CRANE T L, KOCAL T E, et al. Protective activity of different hepatic cytosolic glutathione S-transferases against DNA-binding metabolites of aflatoxin B1. Toxicol Appl Pharmacol 1990; 105: 351-63.
19. ARAKI K, MIYAZAKI J, HINO O, et al. Expression and replication of hepatitis B virus genome in transgenic mice. Proc Natl Acad Sci USA 1989; 86: 207-11.
20. BABINET C, FARZA H, MORELLO D, HADCHOUEL M, POURCEL C. Specific expression of hepatitis B surface antigen (HBsAg) in transgenic mice. Science 1985; 230: 1160-3.
21. FARZA H, HADCHOUEL M, SCOTTO J, TIOLLAIS P, BABINET C, POURCEL C. Replication and gene expression of hepatitis B virus in a transgenic mouse that contains the complete viral genome. J Virol 1988; 62: 4144-52.
22. HINO O, NOMURA K, OHTAKE K, KAWAGUCHI T, SUGANO H, KITAGAWA T. Instability of integrated hepatitis B virus DNA with inverted repeat structure in a transgenic mouse. Cancer Genet Cytogenet 1989; 37: 273-8.
23. CHISARI F V, KLOPCHIN K, MORIYAMA T, et al. Molecular pathogenesis of hepatocellular carcinoma in hepatitis B transgenic mice. Cell 1989; 59: 1145-56.
24. EBLE B E, LINGAPPA V R, GANEM D. Hepatitis B surface antigen: an unusual secreted protein initially synthesized as a transmembrane polypeptide. Mol Cell Biol 1986; 6: 1454-63.
25. PATZER E J, NAKAMURA GR, YAFFE A. Intracelllular transport and secretion of hepatitis B surface antigen in mammalian cells. J Virol 1984; 51: 346-53.
26. McLAHAN A, MILLICH D R, RANEY A K, et al. Expression of hepatitis B surface and core antigens influences of pre-S and precore sequences. J Virol 1987; 61: 780-3.
27. HOOFNAGLE J H, SHAFRITZ D A, POPPER H. Chronic type B hepatitis and the "healthy" HBsAg carrier state. Hepatology 1987; 7: 758-63.
28. SPANDAU D F, LEE C H. Trans-activation of viral enchancers by the hepatitis B virus X protein. J Virol 1987; 62: 427-34.
29. ZAHM P, HOFSCHNEIDER P H, KOSHY R. The HBV X-ORF encodes a transactivator: a potential factor in viral hepatocarcinogenesis. Oncogene 1988; 3: 169-77.
30. CHOMARAT P, SIPOWICZ M A, DIWAN B A, et al. Distinct time courses of increase of cytochromes P450 1A2, 2A and glutathione S-transferases during the progressive hepatitis associates with Helicobacter hepaticus. Carcinogenesis 1997; 18: 2179-90.
31. HARRIS C C, SUN T. Multifactorial etiology of human liver cancer. Carcinogenesis 1984; 5: 697-701.
32. HUANG S N, CHISARI F V. Strong, sustained hepatocellular proliferation precedes hepatocarcinogenesis in hepatitis B surface antigen transgenic mice. Hepatology 1995; 21: 620-5.
33. 1. Proc Natl Acad Sci USA 1990; 87: 4790-3.
34. EATON D L, RAMSDELL H S, NEAL G E. Biotransformation of aflatoxins. In: EATON D L, GROOPMAN J D eds. The toxicology of aflatoxins. Academic Press Inc. 1994: 45-65.
35. 1 metabolism in human liver. PNAS USA 1990; 87: 8306-10.